contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


coegin-introduces-new-tailor-made-follicopeptide-complementary-product-launching-early-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Coegin Pharma är ett svenskt bioteknikföretag med dermakosmetiska projekt för hårtillväxt och hudpigmentering, samt läkemedelskandidater för behandling av hjärtinfarkt och leukemi. Gemensamt för projekten är att de har sin grund i patenterade teknologiplattformar och samarbeten med forskare och akademiker internationellt. Coegin Pharma har sitt huvudkontor i Lund.

Coegin Pharma

Coegin Pharma AB ("Coegin" or "the Company") announces that it has finalized the development of a new, tailor-made Follicopeptide complementary product. It is designed to strengthen existing...

<div class="bequoted-body">Coegin Pharma AB ("Coegin" or "the Company") announces that it has finalized the development of a new, tailor-made Follicopeptide complementary product. It is designed to strengthen existing hair, enhance the performance of Follicopeptide and improve the overall user experience. The new add-on product is expected to reach the market no later than March 2026, marking another strategic step in the commercial expansion of the Follicopeptide ecosystem.Designed to accelerate visible results and strengthen commercial potential The new product is formulated to strengthen the existing hair, revitalize the scalp, increase the receptiveness to Follicopeptide and thereby improve the overall user experience.By adding a complementary product to the Follicopeptide ecosystem, Coegin further strengthens the commercial platform around Follicopeptide, offering new opportunities for increased profitability across the entire distribution chain.Jens Eriksson, CEO of Coegin Pharma, comments: "This new complementary product is a smart and natural extension of our Follicopeptide product portfolio. It enhances the user experience and provides early visible results - something both customers and partners value highly. From a business perspective, it also allows us and our distribution partners to increase margins and build long-term brand loyalty. We have received positive feedback from both existing and potential new partners, who see clear commercial potential in this new addition."Positive partner feedback and early commercial interest&nbsp; The product concept has already been presented to Coegin's existing launch partners as well as potential new distributors, all of whom have expressed enthusiasm for the opportunity to expand their offerings.Dr. John Zibert, Chief Medical Officer at Coegin Pharma, comments:&nbsp; "This product gives us a unique opportunity to further optimize the Follicopeptide experience. By strengthening existing hair and improving scalp receptiveness, we can enhance the effects of Follicopeptide. This is supported by human clinical safety data demonstrating excellent skin compatibility. This new product is an elegant way to create early satisfaction for users while strengthening long-term outcomes."For further information, please contact: Jens Eriksson, CEO, Coegin Pharma AB Email: <a href="mailto:je@coeginpharma.com">je@coeginpharma.com</a>About Coegin Pharma Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.More information - including subscription to company updates and links to social media - is available at <a href="https://www.coeginpharma.com/">coeginpharma.com</a></div><div class="bequoted-files">Attached files<a rel="noopener" href="https://cdn.bequoted.com/media/1/11dc9683-c899-4201-b6cc-8e716dbe70d4/251106-Press-release.pdf">251106-Press-release.pdf</a> </div>

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026